mAbs blocked by pooled macaque and human sera as determined by the mAb-CE.

<p>mAbs blocked by pooled macaque and human sera as determined by the mAb-CE.</p

mAbs competed by human sera as determined by the mAb-CE.

<p>mAbs competed by human sera as determined by the mAb-CE.</p

Percent competition of rhesus and cynomolgus B virus antibody-positive sera by the mAb-CE.

<p>Individual rhesus and cynomolgus macaque serums competed against two Category-I mAbs (12F5.C1 and 12G9.G5) for reactivity with B virus infected cell lysates in mAb-CE, compared to reactivity of one Category-II mAb (7F7.G7), and three Category-III mAbs (7H1.G5, 5D10.C6, and 18D10.F2.A4). The numbers of animals (n) tested in each group are indicated. Values ≥50% competition were regarded as positive competition. Significant, statistically significant (p≤0.05). N.S., statistically not significant (p>0.05).</p

Overall summary of mAbs discussed in this publication and some of their characteristics.

<p>Overall summary of mAbs discussed in this publication and some of their characteristics.</p

The relative reactivity of mAbs to viruses of the simplexvirus group was tested by tELISA.

<p>The relative reactivity of mAbs to viruses of the simplexvirus group was tested by tELISA.</p